Society for Translational Oncology: A Global Mission
The Society for Translational Oncology (STO) is a 501(c)(3) not-for-profit organization that fosters the discovery and clinical translation of important new therapies that enhance the practice of global oncology as well as supports the prevention and treatment of infectious diseases that impact cancer patients and others with weakened immune systems, thus helping protect the vulnerable from life-threatening infections.
Committed to improving patient outcomes, STO bridges a vexing translational gap between drug discovery and approved drug delivery with a portfolio of educational activities for physicians.
STO’s decades-long commitment to translational research and education includes fellowships in both cancer and infectious diseases. The latter has become a critical STO commitment during the COVID-19 pandemic from the global genesis to worldwide distribution of new vaccines and improved therapeutics.
Healthcare professionals are continuously charged with staying on the cutting edge of new medical treatments and technologies. As a professional association dedicated to the continuing education of oncology professionals, STO, founded in 2000, helps improve the quality and safety in caring for cancer patients and others with weakened immune systems by:
- Bringing knowledge and strategies for critical new developments in cancer treatment to the community oncologist
- Bridging the “translational gap” between discovery and delivery of care to the patient
- Providing relevant and compelling educational activities and continuing medical education to help improve the daily practice of physicians, including screening, prevention, diagnosis, treatment, and management of patients with cancer and others with weakened immune systems